InternetIntelligenz 2.0

kostenlos Pressemitteilungen einstellen | veröffentlichen | verteilen

Pressemitteilungen

 

Epigenetics Applications Projected to Generate Revenue $1.60 billion at a CAGR of 13.3%

ID: 1718363

Growing applications in Personalized Medicine and Targeted Therapy in Oncology is a growth opportunity for the Epigenetics market


(IINews) - The key factors that are driving the growth of this market include The decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer.

According to a new market research report "Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) - Global Forecast to 2022", published by MarketsandMarkets™, the market is projected to reach USD 1,605.7 million by 2022 from an estimated USD 854.0 million in 2017, at a CAGR of 13.5% during the forecast period.

Don’t miss out on business opportunities in Epigenetics Technology Market.

Download FREE Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896

Growing applications in Personalized Medicine and Targeted Therapy in Oncology is a growth opportunity for the Epigenetics market

According to a press release published by the Tufts Center for the Study of Drug Development in May 2015, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years, and these investments are further expected to increase by 33% over the next five years. This will further drive the use of epigenetics tools. A 2016 study performed to analyze the epigenetic modification of chronic lymphocytic leukemia (CLL) in the patient population fueled interest in prognostic biomarkers and personalized therapies. This study was performed by CeMM Research Center for Molecular Medicine of the Austrian Academy of Science (Austria) in collaboration with the University of Southampton and the Royal Bournemouth Hospital under the European BLUEPRINT project and the International Human Epigenome Consortium. The expanding application of epigenetics in personalized medicine and targeted therapies, therefore, offers significant opportunities for market growth.





Browse and in-depth TOC on "Epigenetics Market"
191 - Tables
37 - Figures
230 - Pages

Request Sample Pages and Know The Growth Strategies For Revenue Generation:
https://www.marketsandmarkets.com/requestsample.asp?id=896

Among the Application Segments, Oncology Dominated the Global Epigenetics Market in 2016

Based on application, the oncology segment accounted for the largest share of the Epigenetics Market in 2016. The large share of this segment can be attributed to the rising prevalence of cancer and the increasing number of research-related activities.

DNA Methylation Segment Dominated the Epigenetics Market, by Technology in 2016

On the basis of technology, the Epigenetics Market is segmented into DNA methylation, histone modifications, and other technologies (includes non-coding RNA and chromatin remodeling). The DNA methylation segment accounted for the largest share of the Global Epigenetics Market in 2016. The large share of this segment is attributed to the increasing incidence of cancer and the ability of this technique to study different types of cancer with quality outcomes.

North America Dominated the Global Epigenetics Market in 2016

North America accounted for the largest share of the Epigenetics Market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the Epigenetics Market in North America.


Themen in diesem Fachartikel:


Unternehmensinformation / Kurzprofil:

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies'' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets''s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.



Leseranfragen:



PresseKontakt / Agentur:

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales(at)marketsandmarkets.com



drucken  als PDF  an Freund senden  Skyhawk Therapeutics gibt Vertrag mit Takeda zur Entwicklung neuartiger niedermolekularer RNA-Spleißmodifikatoren für neurodegenerative Krankheiten bekannt
Curadev meldet Lizenzvereinbarung mit Takeda für neuartigen STING-Agonisten
Bereitgestellt von Benutzer: dheerajshaha67
Datum: 08.05.2019 - 12:02 Uhr
Sprache: Deutsch
News-ID 1718363
Anzahl Zeichen: 0

Kontakt-Informationen:
Ansprechpartner: Shelly Singh
Stadt:

Northbrook


Telefon: 18886006441

Kategorie:

Biotechnologie


Anmerkungen:


Dieser Fachartikel wurde bisher 165 mal aufgerufen.


Der Fachartikel mit dem Titel:
"Epigenetics Applications Projected to Generate Revenue $1.60 billion at a CAGR of 13.3%
"
steht unter der journalistisch-redaktionellen Verantwortung von

MnM (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von MnM



 

Wer ist Online

Alle Mitglieder: 50.252
Registriert Heute: 0
Registriert Gestern: 1
Mitglied(er) online: 0
Gäste Online: 186


Bitte registrieren Sie sich hier. Als angemeldeter Benutzer nutzen Sie den vollen Funktionsumfang dieser Seite.